2 Lavender (EDTA) blood
Specimens should be collected by blood draw of at least 8 mL into LAV (EDTA) tube(s) (with minimum of 10 million nucleated cells).
Collect
2 Lavender (EDTA) tubes, 8mL total
Storage/Transport Temperature
Store whole blood specimen at 2-8°C
Deliver immediately on ice
Unacceptable Conditions
Specimens other than blood.
Specimens collected in anticoagulants other than EDTA
Severly hemolyzed or clotted specimens.
Frozen specimens
Blood specimens older than 48-72 hours may fail testing due to RNA degradation.
Test Barcode Number
22220
Lab Section
Molecular Diagnostic
Methodology
Multiplex real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR) for the e13a2 (b2a2) and e14a2 (b3a2) transcripts, both of which encode a p210 protein
Commercial kit: FDA-cleared Asuragen QuantideX qPCR BCR-ABL IS kit
Reporting Structure: BCR-ABL1 transcript levels are reported as:
1) %IS values: percent ratio of BCR-ABL1 to ABL1 expressed on the International Scale (IS)
2) Molecular Reduction (MR) values; logarithmic decrease from the baseline of 100%IS or MR0
Table 1: Relationship between %IS and MR values.
MR
%IS
0.0
100
0.5
32
1.0
10
1.5
3.2
2.0
1
2.5
0.32
3.0
0.1
3.5
0.032
4.0
0.01
4.5
0.0032
4.7
0.002
5.0
0.001
Of note, the IS is a numeric scale anchored to the standardized baseline of 100%IS that was established by the International Randomized Study of Interferon and STI571 (IRIS) trial. This baseline was derived from the median BCR-ABL1:BCR transcript levels of 30 CML patients at diagnosis (PMID: 14534335). Log reductions (i.e. MR values) reflect the decrease in BCR-ABL1:ABL1 transcript levels from the IRIS study baseline of 100%IS, not the decrease from a given patient's pre-treatment level.
Interpretative considerations: Only BCR-ABL1:ABL1 changes of 0.5 log or greater should be considered significant.
Reportable Range of Quantitation: 0.002%IS (MR4.7) - 50%IS (MR0.3)
Results cannot be accurately quantitated outside of the reportable range. Results below or above these values will be reported as "Positive, below the lower limit of quantitation (LOQ) or "Positive, above the upper limit of quantitation (LOQ)," respectively. Some patients with very low levels of BCR-ABL1 transcript (<0.002%IS, >MR4.7) may be reported as "Negative". Therefore, a "Negative" result does not preclude the presence of low levels of leukemic cells in the patient. This assay does not detect p190 or p230 transcripts.
Interpretive Data
CPT Codes
81206
LOINC Mapping
69380-4
Group Test Information
Result Test ID
Reportable
Result Test Name
Result Type
Type (Alpha or Numeric)
Prompt Test
TYPM8
Y
SPECIMEN TYPRE, MBCR
I
A
CAS#4
Y
PATH CASE #,MBCR
I
A
MBCRR
Y
Mbcr/abl
I
A
MBCIS
Y
%IS
I
A
MBCQR
Y
Mbcrlabl QUANT
I
A
INTMB
Y
INTERPRETATION,MBCR
I
A
REVMB
Y
REVIEWED BY:
I
A
CPT Codes
81206
LOINC Mapping
69380-4
Specimen Requirements
Collection Instructions
2 Lavender (EDTA) blood
Specimens should be collected by blood draw of at least 8 mL into LAV (EDTA) tube(s) (with minimum of 10 million nucleated cells).
Collect
2 Lavender (EDTA) tubes, 8mL total
Storage/Transport Temperature
Store whole blood specimen at 2-8°C
Deliver immediately on ice
Unacceptable Conditions
Specimens other than blood.
Specimens collected in anticoagulants other than EDTA
Severly hemolyzed or clotted specimens.
Frozen specimens
Blood specimens older than 48-72 hours may fail testing due to RNA degradation.
Test Barcode Number
22220
Testing
Lab Section
Molecular Diagnostic
Methodology
Multiplex real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR) for the e13a2 (b2a2) and e14a2 (b3a2) transcripts, both of which encode a p210 protein
Commercial kit: FDA-cleared Asuragen QuantideX qPCR BCR-ABL IS kit
Reporting Structure: BCR-ABL1 transcript levels are reported as:
1) %IS values: percent ratio of BCR-ABL1 to ABL1 expressed on the International Scale (IS)
2) Molecular Reduction (MR) values; logarithmic decrease from the baseline of 100%IS or MR0
Table 1: Relationship between %IS and MR values.
MR
%IS
0.0
100
0.5
32
1.0
10
1.5
3.2
2.0
1
2.5
0.32
3.0
0.1
3.5
0.032
4.0
0.01
4.5
0.0032
4.7
0.002
5.0
0.001
Of note, the IS is a numeric scale anchored to the standardized baseline of 100%IS that was established by the International Randomized Study of Interferon and STI571 (IRIS) trial. This baseline was derived from the median BCR-ABL1:BCR transcript levels of 30 CML patients at diagnosis (PMID: 14534335). Log reductions (i.e. MR values) reflect the decrease in BCR-ABL1:ABL1 transcript levels from the IRIS study baseline of 100%IS, not the decrease from a given patient's pre-treatment level.
Interpretative considerations: Only BCR-ABL1:ABL1 changes of 0.5 log or greater should be considered significant.
Reportable Range of Quantitation: 0.002%IS (MR4.7) - 50%IS (MR0.3)
Results cannot be accurately quantitated outside of the reportable range. Results below or above these values will be reported as "Positive, below the lower limit of quantitation (LOQ) or "Positive, above the upper limit of quantitation (LOQ)," respectively. Some patients with very low levels of BCR-ABL1 transcript (<0.002%IS, >MR4.7) may be reported as "Negative". Therefore, a "Negative" result does not preclude the presence of low levels of leukemic cells in the patient. This assay does not detect p190 or p230 transcripts.